Becton Dickinson and Co (BDX):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Becton Dickinson and Co (BDX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7307
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:208
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instruments. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management systems; prefillable drug delivery systems; respiratory ventilation and diagnostics equipment and consumables; products for the safe collection and transport of diagnostics specimens; instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers and various clinical research tools. BD offers its products to life science researchers, healthcare institutions, clinical laboratories, pharmaceutical industry and general public. The company sells its products in the Americas, Europe, the Middle East, Africa and Asia-Pacific. BD is headquartered in New Jersey, the US.

Becton Dickinson and Co (BDX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 9
Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Becton Dickinson and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Becton Dickinson and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 13
Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 15
Becton Dickinson and Co, Medical Equipment, Deal Details 21
Asset Purchase 21
Becton, Dickinson Rumored to Sell Respiratory Devices Business 21
C. R. Bard Acquires Technology from 3DT Holdings 22
Venture Financing 23
MeMed Raises USD70 Million in Financing Round 23
Medaware Raises USD8 Million in Series A Financing 25
TVA Medical Raises USD15 Million in Series C Financing 26
Embo Medical Raises USD3.7 Million in Seed Funding 27
Vascular Pathways Secures USD5 Million from Square 1 Bank 28
Vascular Pathways Raises USD5.5 Million in Venture Financing 29
TVA Medical Raises US$9.5 Million In Series B Venture Financing 30
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 31
Private Equity 32
Apax Partners to Acquire Remaining Minority Stake in Vyaire Medical for USD435 Million 32
UK Medical’s Managment Acquires Company from Becton Dickinson 33
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 34
Partnerships 35
Roche Enters into Licensing Agreement with Becton Dickinson 35
Vancive Medical Enters Into Licensing Agreement With CareFusion For Antimicrobial Dressing 36
Asuragen Enters Into Licensing Agreement With Becton, Dickinson 37
SDIX Enters Into Licensing Agreement With BD Diagnostic 38
Noble Enters into Agreement with Becton Dickinson 39
Becton Dickinson and UniteOR Enter into Agreement 40
Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 41
Becton, Dickinson Forms Joint Venture with Apax Partners 42
Becton Dickinson and Singapore Immunology Network Enter into Research Agreement 43
Becton, Dickinson Enters into Distribution Agreement with Check-Points 44
Becton, Dickinson Enters into Co-Marketing Agreement with Sight Diagnostics 45
CareFusion Enters into Distribution Agreement with ResMed 46
CareFusion Enters into Distribution Agreement with AAM Healthcare 47
Edwards Lifesciences Enters into Agreement with CareFusion 48
Seegene Enters into Co-Development Agreement with BD Life Sciences 49
Becton, Dickinson Enters into Agreement with FlowJo 50
BD Life Sciences Enters into Co-Marketing with Cellular Research 51
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 52
CareFusion Enters into Distribution Agreement with Breas Medical for Vivo Line of Ventilators 53
Boston Scientific Enters into Distribution Agreement with C. R. Bard for Lutonix DCB 54
Becton, Dickinson Enters into Agreement with Aethon to Develop Integrated Medication Management Solution 55
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 56
Terumo Enters Into Distribution Agreement With CareFusion For SurFlash Catheters In US 57
Becton, Dickinson Enters Into Collaboration Agreement With CME Medical For Saf-T-Intima Safety Integrated IV Catheter System 58
Juvenile Diabetes Research Extends Co-Development Agreement With Becton, Dickinson For Infusion And Glucose Monitoring Device 59
BD Diagnostics Amends Agreement With Bruker For BD Bruker Maldi Biotyper System 60
CytoVas And BD Biosciences Enter Into Co-Development Agreement For Vascular Health Diagnostics 61
Intelligent Hospital Systems Enters Into Technology Integration Agreement With Cato Software Solutions 62
BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 63
University of Limerick Enters Into Co-Development Agreement With GenCell 64
Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 65
Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 66
CareFusion Extends Distribution Agreement With Fisher & Paykel Healthcare 67
Becton, Dickinson Enters into Licensing Agreement with DiabetOmics 68
Equity Offering 69
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 69
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 71
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 73
Debt Offering 74
Becton, Dickinson Raises USD374 Million in Public offering of 0.368% Notes Due 2019 74
Becton Dickinson Raises USD337.4 Million in Public Offering of 3.02% Notes Due 2025 75
Becton Dickinson Raises USD354.4 Million in Public Offering of 1.401% Notes Due 2023 76
Becton, Dickinson Raises USD 826.05 Million in Public Offering of 0.368% Notes Due 2019 77
Becton, Dickinson Raises USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 78
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 79
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 80
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 81
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 82
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 83
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 84
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 85
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 87
C. R. Bard Raises USD500 Million in Public Offering of 3% Notes Due 2026 89
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 90
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 92
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 94
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 96
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 98
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 100
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 101
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 103
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 104
C. R. Bard Raises USD500 Million in Public Offering of 1.375% Notes Due 2018 105
Asset Transactions 106
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 106
Merit Medical Acquires Product Line from Becton, Dickinson for USD100 Million 107
Stryker Acquires Vertebral Augmentation Solutions Business from Becton, Dickinson 109
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 110
Becton, Dickinson May Divest Surgical Instruments Unit 111
Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For US$730 Million 112
Natus Medical Completes Acquisition Of Nicolet Business From CareFusion For US$58 Million 114
Acquisition 116
Becton Dickinson Acquires TVA Medical 116
Vyaire Medical Acquires Acutronic Medical Systems 117
Becton, Dickinson Acquires C. R. Bard for USD24 Billion 118
Becton, Dickinson Acquires Remaining 60% Stake in Caesarea Medical Electronics 120
C. R. Bard Acquires Liberator Medical for USD181 Million 121
C. R. Bard Acquires Embo Medical 123
C. R. Bard Acquires 50% Joint Venture Interest in Medicon from Kobayashi Pharma 124
Becton, Dickinson Acquires Cellular Research 125
C. R. Bard Acquires Vascular Pathways from MVM Life Science Partners 126
C. R. Bard Acquires Vascular Pathways Europe from MVM Life Science Partners 127
Becton, Dickinson Acquires CareFusion for USD12.2 Billion 128
BD Acquires CRISI Medical Systems 130
Becton, Dickinson Acquires GenCell Biosystems 131
Becton, Dickinson Acquires Alverix From Safeguard Scientifics And New Venture Partners For US$40 Million 132
CareFusion Completes Partial Acquisition Of Vital Signs From GE Healthcare For US$470 Million 134
C. R. Bard Completes Acquisition Of Rochester Medical For US$262 Million 135
Boston Scientific Completes Acquisition of Bard Electrophysiology From C. R. Bard For US$275 Million 136
CareFusion Acquires Stake In Sendal From GED Capital 138
Davol Completes Acquisition Of Medafor 139
C. R. Bard Acquires Loma Vista Medical 140
Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions 141
Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 142
Carefusion Completes Acquisition Of Intermed Equipamento Medico Hospitalar, Respiratory Device Company 143
C. R. Bard Acquires Neomend, Developer Of Wound Healing Products, For Up To US$165 Million 144
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 146
CareFusion Acquires UK Medical, Distributor Of Medical Products 148
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 149
Becton Dickinson and Co – Key Competitors 150
Becton Dickinson and Co – Key Employees 151
Becton Dickinson and Co – Locations And Subsidiaries 153
Head Office 153
Other Locations & Subsidiaries 153
Recent Developments 160
Strategy And Business Planning 160
Oct 25, 2017: BD Breaks Ground on $60 Million Expansion of Nebraska Manufacturing Facility 160
Jun 13, 2017: FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration 161
May 09, 2017: BD and UniteOR to develop new surgical tray management solution 162
Financial Announcements 163
Aug 02, 2018: BD announces results for 2018 third fiscal quarter; raises fiscal 2018 revenue guidance 163
May 03, 2018: BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance 165
Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard 167
Aug 03, 2017: BD Announces Results For 2017 Third Fiscal Quarter 169
May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 171
Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 173
Corporate Communications 175
Aug 16, 2018: BD elects Jeffrey Henderson to board of directors 175
Aug 01, 2018: BD appoints Simon Campion to Interventional Segment President 176
Jun 01, 2018: BD Appoints John DeFord As Chief Technology Officer 177
Apr 27, 2018: BD Names Three Executives to Segment Leadership Roles 178
Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 179
Legal and Regulatory 180
Jan 11, 2018: FDA warns Becton Dickinson & Company of significant violations of the law as part of ongoing investigation into lead testing issues 180
Oct 31, 2017: Eastern District Court Denies Motion to Reconsider Becton, Dickinson and Co. Judgment 181
Sep 15, 2017: Retractable Technologies Files Motions in Connection with Becton, Dickinson Judgment 182
Aug 18, 2017: District Court Issues Final Judgment – Retractable Technologies v. Becton, Dickinson 183
Mar 21, 2017: Retractable Technologies Announces Litigation Updates 184
Government and Public Interest 185
Jun 27, 2018: BD, Heart to Heart International and the NAFC Announce 2018 Grantees for a Multi-Year Point of Care Testing Initiative to Improve Patient Outcomes 185
Mar 22, 2018: Statement from FDA’s Donald St. Pierre on findings from ongoing investigation into lead testing issues 186
Dec 11, 2017: BD Establishes Product Security Partnership Program to Enhance Cybersecurity of Medical Technology 187
Jun 06, 2017: BD Releases 2016 Sustainability Report 189
Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 190
Product News 191
Jul 26, 2018: BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis 191
Jun 20, 2018: BD to Demonstrate Expanded Vascular Access Offerings from Insertion to Removal during the 5th World Congress on Vascular Access (WoCoVA) 192
Mar 27, 2018: BD Field Safety Notice on Vacutainer Citrate Plus Blood Collection Tubes 193
Mar 05, 2018: BD to Demonstrate Enhanced Integration Offerings that Target Key Gaps Across the Medication Management Process at HIMSS18 194
Dec 04, 2017: BD Announces New Offerings to Help Customers Deliver Safer, Simpler and Smarter Medication Management 196
Nov 16, 2017: BD to Introduce Integrated Medication Management Platform Designed to Address Hospitals’ Greatest Challenges at ASHP17 197
Apr 27, 2017: BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering 198
Feb 20, 2017: BD Demonstrates Synchronized Technology Platform at HIMSS17 199
Other Significant Developments 200
Mar 22, 2018: BD Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes 200
Feb 14, 2018: Attivo Networks Receives Validation for Attivo BOTsink Deception-Based Threat Detection through BD Product Security Partnership Program 201
Feb 01, 2018: BD Launches New Los Angeles County Program to Equip Patients with Essential Resources for Safe Sharps Disposal 202
Aug 24, 2017: BD Helps Thun Hospital Advance Medication Management Into the Future 203
Jul 18, 2017: BD Transforms Microbiology Urine Testing 205
May 09, 2017: BD and UniteOR to develop new surgical tray management solution 206
Feb 13, 2017: BD Announces Early Access Program for BD Resolve Single-Cell Analysis Platform 207
Appendix 208
Methodology 208
About GlobalData 208
Contact Us 208
Disclaimer 208

List of Tables
Becton Dickinson and Co, Medical Equipment, Key Facts, 2017 2
Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Becton Dickinson and Co, Medical Equipment Deals By Type, 2012 to YTD 2018 11
Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Becton Dickinson and Co, Deals By Market, 2012 to YTD 2018 13
Becton Dickinson and Co, Medical Equipment, Deals Summary, 2012 to YTD 2018 15
Becton, Dickinson Rumored to Sell Respiratory Devices Business 21
C. R. Bard Acquires Technology from 3DT Holdings 22
MeMed Raises USD70 Million in Financing Round 23
Medaware Raises USD8 Million in Series A Financing 25
TVA Medical Raises USD15 Million in Series C Financing 26
Embo Medical Raises USD3.7 Million in Seed Funding 27
Vascular Pathways Secures USD5 Million from Square 1 Bank 28
Vascular Pathways Raises USD5.5 Million in Venture Financing 29
TVA Medical Raises US$9.5 Million In Series B Venture Financing 30
GenCell Biosystems Raises US$3.5 Million In Seed Financing Round 31
Apax Partners to Acquire Remaining Minority Stake in Vyaire Medical for USD435 Million 32
UK Medical’s Managment Acquires Company from Becton Dickinson 33
CareFusion Reportedly Elicits Acquisition Interest From Private Equity Firms 34
Roche Enters into Licensing Agreement with Becton Dickinson 35
Vancive Medical Enters Into Licensing Agreement With CareFusion For Antimicrobial Dressing 36
Asuragen Enters Into Licensing Agreement With Becton, Dickinson 37
SDIX Enters Into Licensing Agreement With BD Diagnostic 38
Noble Enters into Agreement with Becton Dickinson 39
Becton Dickinson and UniteOR Enter into Agreement 40
Becton, Dickinson Enters into Research Agreement with Juvenile Diabetes Research Foundation 41
Becton, Dickinson Forms Joint Venture with Apax Partners 42
Becton Dickinson and Singapore Immunology Network Enter into Research Agreement 43
Becton, Dickinson Enters into Distribution Agreement with Check-Points 44
Becton, Dickinson Enters into Co-Marketing Agreement with Sight Diagnostics 45
CareFusion Enters into Distribution Agreement with ResMed 46
CareFusion Enters into Distribution Agreement with AAM Healthcare 47
Edwards Lifesciences Enters into Agreement with CareFusion 48
Seegene Enters into Co-Development Agreement with BD Life Sciences 49
Becton, Dickinson Enters into Agreement with FlowJo 50
BD Life Sciences Enters into Co-Marketing with Cellular Research 51
Selah Genomics, Greenville Health, DecisionQ and Becton Dickinson Enter into Agreement 52
CareFusion Enters into Distribution Agreement with Breas Medical for Vivo Line of Ventilators 53
Boston Scientific Enters into Distribution Agreement with C. R. Bard for Lutonix DCB 54
Becton, Dickinson Enters into Agreement with Aethon to Develop Integrated Medication Management Solution 55
GenCell Biosystems To Enter Into Agreement With Fiocruz, Institute Of Molecular Biology Of Parana And Immunobiological Technology Institute To Develop Clinical Screening Systems 56
Terumo Enters Into Distribution Agreement With CareFusion For SurFlash Catheters In US 57
Becton, Dickinson Enters Into Collaboration Agreement With CME Medical For Saf-T-Intima Safety Integrated IV Catheter System 58
Juvenile Diabetes Research Extends Co-Development Agreement With Becton, Dickinson For Infusion And Glucose Monitoring Device 59
BD Diagnostics Amends Agreement With Bruker For BD Bruker Maldi Biotyper System 60
CytoVas And BD Biosciences Enter Into Co-Development Agreement For Vascular Health Diagnostics 61
Intelligent Hospital Systems Enters Into Technology Integration Agreement With Cato Software Solutions 62
BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 63
University of Limerick Enters Into Co-Development Agreement With GenCell 64
Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 65
Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 66
CareFusion Extends Distribution Agreement With Fisher & Paykel Healthcare 67
Becton, Dickinson Enters into Licensing Agreement with DiabetOmics 68
Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 69
Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 71
Becton, Dickinson Files Registration Statement For Public Offering Of Securities 73
Becton, Dickinson Raises USD374 Million in Public offering of 0.368% Notes Due 2019 74
Becton Dickinson Raises USD337.4 Million in Public Offering of 3.02% Notes Due 2025 75
Becton Dickinson Raises USD354.4 Million in Public Offering of 1.401% Notes Due 2023 76
Becton, Dickinson Raises USD 826.05 Million in Public Offering of 0.368% Notes Due 2019 77
Becton, Dickinson Raises USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 78
Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 79
Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 80
Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 81
Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 82
Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 83
Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 84
Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 85
Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 87
C. R. Bard Raises USD500 Million in Public Offering of 3% Notes Due 2026 89
Becton, Dickinson Raises USD1.2 Billion in Public Offering of 4.685% Notes Due 2044 90
Becton, Dickinson Raises USD1.75 Billion in Public Offering of 3.734% Notes Due 2024 92
Becton, Dickinson Raises USD750 Million in Public Offering of Floating Rate Notes Due 2016 94
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 1.8% Notes Due 2017 96
Becton, Dickinson Raises USD1.25 Billion in Public Offering of 2.675% Notes Due 2019 98
CareFusion Raises USD300 Million in Public Offering of Notes Due 2044 100
CareFusion Raises USD300 Million in Private Placement of Notes Due 2017 101
CareFusion Raises USD400 Million in Public Offering of Notes Due 2024 103
CareFusion Completes Private Placement Of Notes Due 2023 For US$300 Million 104
C. R. Bard Raises USD500 Million in Public Offering of 1.375% Notes Due 2018 105
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from Becton, Dickinson and Company 106
Merit Medical Acquires Product Line from Becton, Dickinson for USD100 Million 107
Stryker Acquires Vertebral Augmentation Solutions Business from Becton, Dickinson 109
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 110
Becton, Dickinson May Divest Surgical Instruments Unit 111
Corning Completes Acquisition of Majority Stake In Discovery Labware Unit Of Becton, Dickinson For US$730 Million 112
Natus Medical Completes Acquisition Of Nicolet Business From CareFusion For US$58 Million 114
Becton Dickinson Acquires TVA Medical 116
Vyaire Medical Acquires Acutronic Medical Systems 117
Becton, Dickinson Acquires C. R. Bard for USD24 Billion 118
Becton, Dickinson Acquires Remaining 60% Stake in Caesarea Medical Electronics 120
C. R. Bard Acquires Liberator Medical for USD181 Million 121
C. R. Bard Acquires Embo Medical 123
C. R. Bard Acquires 50% Joint Venture Interest in Medicon from Kobayashi Pharma 124
Becton, Dickinson Acquires Cellular Research 125
C. R. Bard Acquires Vascular Pathways from MVM Life Science Partners 126
C. R. Bard Acquires Vascular Pathways Europe from MVM Life Science Partners 127
Becton, Dickinson Acquires CareFusion for USD12.2 Billion 128
BD Acquires CRISI Medical Systems 130
Becton, Dickinson Acquires GenCell Biosystems 131
Becton, Dickinson Acquires Alverix From Safeguard Scientifics And New Venture Partners For US$40 Million 132
CareFusion Completes Partial Acquisition Of Vital Signs From GE Healthcare For US$470 Million 134
C. R. Bard Completes Acquisition Of Rochester Medical For US$262 Million 135
Boston Scientific Completes Acquisition of Bard Electrophysiology From C. R. Bard For US$275 Million 136
CareFusion Acquires Stake In Sendal From GED Capital 138
Davol Completes Acquisition Of Medafor 139
C. R. Bard Acquires Loma Vista Medical 140
Becton, Dickinson Acquires Cato Software Solutions, Maker Of Medical Software Solutions 141
Becton, Dickinson Completes Acquisition Of Safety Syringes, Developer Of Anti-Needlestick Devices 142
Carefusion Completes Acquisition Of Intermed Equipamento Medico Hospitalar, Respiratory Device Company 143
C. R. Bard Acquires Neomend, Developer Of Wound Healing Products, For Up To US$165 Million 144
Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 146
CareFusion Acquires UK Medical, Distributor Of Medical Products 148
Becton, Dickinson Acquires KIESTRA, Provider Of Lab Automation Solutions 149
Becton Dickinson and Co, Key Competitors 150
Becton Dickinson and Co, Key Employees 151
Becton Dickinson and Co, Other Locations 153
Becton Dickinson and Co, Subsidiaries 154

List of Figures
Becton Dickinson and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Becton Dickinson and Co, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Becton Dickinson and Co, Medical Equipment, Deals By Year, 2012 to YTD 2018 10
Becton Dickinson and Co, Medical Equipment, Deals by Type, 2012 to YTD 2018 11
Becton Dickinson and Co, Medical Equipment, Deals By Region, 2012 to YTD 2018 12
Becton Dickinson and Co, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

★海外企業調査レポート[Becton Dickinson and Co (BDX):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cipher Pharmaceuticals Inc (CPH):企業の財務・戦略的SWOT分析
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Energen Corporation:企業の戦略・SWOT・財務情報
    Energen Corporation - Strategy, SWOT and Corporate Finance Report Summary Energen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Alamo Group Inc (ALG):企業の財務・戦略的SWOT分析
    Alamo Group Inc (ALG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hammond Power Solutions Inc (HPS.A):企業の財務・戦略的SWOT分析
    Hammond Power Solutions Inc (HPS.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Kyocera Corporation:企業の戦略・SWOT・財務情報
    Kyocera Corporation - Strategy, SWOT and Corporate Finance Report Summary Kyocera Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SOGLASIE Insurance Company Ltd.:企業の戦略・SWOT・財務情報
    SOGLASIE Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary SOGLASIE Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Kkr Financial Holdings Llc
    Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report Summary Kkr Financial Holdings Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • AusGroup Ltd (5GJ):企業の財務・戦略的SWOT分析
    Summary AusGroup Ltd (AusGroup) is a provider of project and asset services. The company operates through its subsidiaries, namely, MAS, AGC, and NT Port and Marine. Its major services include mechanical and piping, scaffolding, multidisciplinary maintenance services, fabrication & management, elect …
  • Silverleaf Resorts, Inc.
    Silverleaf Resorts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Silverleaf Resorts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Alacer Gold Corp:企業の戦略・SWOT・財務分析
    Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Alacer Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • InVivoScribe Technologies Inc:企業の製品パイプライン分析
    Summary InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company offer full range of hematology-oncology testing products and services. It’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent de …
  • Premier Inc (PINC):医療機器:M&Aディール及び事業提携情報
    Summary Premier Inc (Premier) is a provider of healthcare solutions. It is an alliance of hospitals, health systems, physicians and other healthcare providers in the US. The alliance enables the owners to share services and programs aimed at improving the quality and cost-effectiveness of clinical o …
  • Swiss Life Holding Ltd:企業のM&A・事業提携・投資動向
    Swiss Life Holding Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Swiss Life Holding Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Sing Investments & Finance Limited (S35):企業の財務・戦略的SWOT分析
    Sing Investments & Finance Limited (S35) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Beactica AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Beactica AB (Beactica) is a drug discovery company develops a pipeline of novel and mechanistically defined small molecule therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate ana …
  • Marcegaglia SpA:企業の戦略・SWOT・財務情報
    Marcegaglia SpA - Strategy, SWOT and Corporate Finance Report Summary Marcegaglia SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sensus BV:企業の戦略・SWOT・財務情報
    Sensus BV - Strategy, SWOT and Corporate Finance Report Summary Sensus BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • NuScale Power LLC:企業の戦略的SWOT分析
    NuScale Power LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • WGL Holdings Inc (WGL):石油・ガス:M&Aディール及び事業提携情報
    Summary WGL Holdings Inc (WGL) is an energy holding company that delivers natural gas, and provides energy-related products and services to customers. It also offers design-build energy efficient and sustainable solutions and water and energy-related infrastructure services. The company delivers an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆